DiaRem2: Incorporating duration of diabetes to improve prediction of diabetes remission after metabolic surgery

The DiaRem score was designed to provide a simple, preoperative tool for predicting the likelihood of type 2 diabetes (T2D) remission after Roux-en-Y gastric bypass (RYGB) surgery [1]. The original version of DiaRem (hereafter referred to as DiaRem) used components that are usually known to patients with T2D and their providers, including age, hemoglobin A1C level (HbA1C), and types of T2D medications, compared with other prediction tools, DiaRem is easy to use, has the lowest prediction error [2] and it has been validated in multiple and varied RYGB cohorts [3 –7].
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Tags: Original article Source Type: research